Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer.

An uncontrolled, single-group, multicenter, investigator-initiated study of adjuvant paclitaxel and trastuzumab in 406 patients with tumors measuring up to 3 cm in greatest dimension, which found that the primary end point was survival free from invasive disease.